University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
Rowett Institute and the Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK.
Sci Rep. 2020 Feb 24;10(1):3259. doi: 10.1038/s41598-020-59982-5.
Seipin deficiency causes severe congenital generalized lipodystrophy (CGL) and metabolic disease. However, how seipin regulates adipocyte development and function remains incompletely understood. We previously showed that seipin acts as a scaffold protein for AGPAT2, whose disruption also causes CGL. More recently, seipin has been reported to promote adipogenesis by directly inhibiting GPAT3, leading to the suggestion that GPAT inhibitors could offer novel treatments for CGL. Here we investigated the interactions between seipin, GPAT3 and AGPAT2. We reveal that seipin and GPAT3 associate via direct interaction and that seipin can simultaneously bind GPAT3 and AGPAT2. Inhibiting the expression of seipin, AGPAT2 or GPAT3 led to impaired induction of early markers of adipocyte differentiation in cultured cells. However, consistent with normal adipose mass in GPAT3-null mice, GPAT3 inhibition did not prevent the formation of mature adipocytes. Nonetheless, loss of GPAT3 in seipin-deficient preadipocytes exacerbated the failure of adipogenesis in these cells. Thus, our data indicate that GPAT3 plays a modest positive role in adipogenesis and argue against the potential of GPAT inhibitors to rescue white adipose tissue mass in CGL2. Overall, our study reveals novel mechanistic insights regarding the molecular pathogenesis of severe lipodystrophy caused by mutations in either seipin or AGPAT2.
Seipin 缺乏会导致严重的先天性全身性脂肪营养不良 (CGL) 和代谢疾病。然而,seipin 如何调节脂肪细胞的发育和功能仍不完全清楚。我们之前曾表明,seipin 作为 AGPAT2 的支架蛋白发挥作用,其破坏也会导致 CGL。最近,有报道称 seipin 通过直接抑制 GPAT3 来促进脂肪生成,这表明 GPAT 抑制剂可能为 CGL 提供新的治疗方法。在这里,我们研究了 seipin、GPAT3 和 AGPAT2 之间的相互作用。我们揭示了 seipin 和 GPAT3 通过直接相互作用相关联,并且 seipin 可以同时结合 GPAT3 和 AGPAT2。抑制 seipin、AGPAT2 或 GPAT3 的表达会导致培养细胞中脂肪细胞分化早期标志物的诱导受损。然而,与 GPAT3 缺失小鼠的正常脂肪量一致,GPAT3 抑制并未阻止成熟脂肪细胞的形成。尽管如此,在 seipin 缺陷的前脂肪细胞中丧失 GPAT3 会加剧这些细胞中脂肪生成的失败。因此,我们的数据表明 GPAT3 在脂肪生成中发挥适度的正作用,并反对 GPAT 抑制剂在 CGL2 中挽救白色脂肪组织质量的潜力。总体而言,我们的研究揭示了由 seipin 或 AGPAT2 突变引起的严重脂肪营养不良的分子发病机制的新机制见解。